Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | APP | P05067 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 2/20 | 0.50 |
| ▸ | ALPG | P10696 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8390778 | 1.00 | INSR (1.00) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL24046417 | 0.85 | INSR (0.73) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL9308820 | 0.85 | INSR (0.73) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL24046416 | 0.83 | INSR (0.70) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL24046586 | 0.83 | INSR (0.70) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL1306153 | 0.82 | INSR (0.69) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL1306156 | 0.82 | INSR (0.69) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL24693082 | 0.82 | MAPT (0.74) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL10819273 | 0.82 | MAPT (0.74) | INSRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL19736224 | 0.82 | MAPT (0.74) | INSRMAPTRAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6001331-A | INTRODUCING INTO PATIENT BENZYLTHIAZOL-3-IUM DERIVATIVES OF GIVEN FORMULA; ALLOWING TIME FOR COMPOUND TO ASSOCIATE WITH AMYLOID; DETECTING THE LABELED COMPOUND ASSOCIATED WITH AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | claimed |
| WO-1997026919-A2 | METHOD OF IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 1997-07-31 | — | — | WO | claimed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220387411-A1 | TARGETED AUTOPHAGY CONJUGATES AND METHODS | VULCAN BIO CORPORATION | 2022-12-08 | — | — | US | disclosed |
| WO-2019183600-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-6001331-A | INTRODUCING INTO PATIENT BENZYLTHIAZOL-3-IUM DERIVATIVES OF GIVEN FORMULA; ALLOWING TIME FOR COMPOUND TO ASSOCIATE WITH AMYLOID; DETECTING THE LABELED COMPOUND ASSOCIATED WITH AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1997026919-A2 | METHOD OF IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387411-A1 | TARGETED AUTOPHAGY CONJUGATES AND METHODS | ATG7, BECN1, SQSTM1 | INSR 2446/4885MAPT 198/4885RAB9A 126/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | INSR 2484/4885MAPT 442/4885RAB9A 223/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | INSR 2484/4885MAPT 442/4885RAB9A 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.